PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.\', \'Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.\', \'Institute for Safe Medication Practices, Alexandria, Virginia, USA.\', \'Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public health, Baltimore, Maryland, USA.\', \'Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA galexan9@jhmi.edu.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1136/bmjopen-2020-039978
?:doi
?:hasPublicationType
?:journal
  • BMJ open
is ?:pmid of
?:pmid
?:pmid
  • 32518212
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.372
?:rankingScore_hIndex
  • 57
?:title
  • Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32518212>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32518212>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all